Adachi J, Mishima K, Wakiya K et al (2012) O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neurooncol 107:147–153

Article  CAS  PubMed  Google Scholar 

Aibaidula A, Chan AKY, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327–1337

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77

Article  CAS  PubMed  Google Scholar 

Berzero G, Di Stefano AL, Ronchi S et al (2021) IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955–966

Article  CAS  PubMed  Google Scholar 

Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: Recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 136:805–810

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404

Article  PubMed  Google Scholar 

Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2015) The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neurooncol 121:359–364

Article  PubMed  Google Scholar 

Dono A, Zhu P, Takayasu T et al (2024) Extent of resection thresholds in molecular subgroups of newly diagnosed isocitrate dehydrogenase-wildtype glioblastoma. Neurosurgery 95:932–940

Article  PubMed  Google Scholar 

Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:261

Article  Google Scholar 

Grogan D, Bray DP, Cosgrove M et al (2022) Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review. J Neurooncol 157:187–195

Article  PubMed  PubMed Central  Google Scholar 

Guo X, Gu L, Li Y et al (2023) Histological and molecular glioblastoma, IDH-wildtype: A real-world landscape using the 2021 WHO classification of central nervous system tumors. Front Oncol 13:1200815

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higa N, Akahane T, Yokoyama S et al (2020) A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Cancer Sci 111:3902–3911

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higa N, Akahane T, Yokoyama S et al (2022) Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma. Neurooncol Adv 4:vdac097

PubMed  PubMed Central  Google Scholar 

Hirose Y, Sasaki H, Abe M et al (2013) Subgrouping of gliomas on the basis of genetic profiles. Brain Tumor Pathol 30:203–208

Article  CAS  PubMed  Google Scholar 

Koo H, Choi SW, Cho HJ et al (2020) Ethnic delineation of primary glioblastoma genome. Cancer Med 9:7352–7359

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lassman AB, Aldape KD, Ansell PJ et al (2019) Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. J Neurooncol 144:205–210

Article  PubMed  PubMed Central  Google Scholar 

Liang J, Lv X, Lu C et al (2020) Prognostic factors of patients with gliomas—an analysis on 335 patients with glioblastoma and other forms of gliomas. BMC Cancer 20:35

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makino R, Higa N, Akahane T et al (2023) Alterations in EGFR and PDGFRA are associated with the localization of contrast-enhancing lesions in glioblastoma. Neurooncol Adv 5:vdad110

PubMed  PubMed Central  Google Scholar 

Mo Z, Xin J, Chai R, Woo PYM, Chan DTM, Wang J (2022) Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations. Cancer Biol Med 19:1440–1459

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muench A, Teichmann D, Spille D et al (2023) A novel type of IDH-wildtype glioma characterized by gliomatosis cerebri-like growth pattern, TERT promoter mutation, and distinct epigenetic profile. Am J Surg Pathol 47:1364–1375

Article  PubMed  Google Scholar 

Nakasu S, Deguchi S, Nakasu Y (2023) IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis. Brain Tumor Pathol 40:143–157

Article  CAS  PubMed  Google Scholar 

Ostrom QT, Shoaf ML, Cioffi G et al (2023) National-level overall survival patterns for molecularly defined diffuse glioma types in the United States. Neuro Oncol 25:799–807

Article  CAS  PubMed  Google Scholar 

Ramos-Fresnedo A, Pullen MW, Perez-Vega C et al (2022) The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol 157:177–185

Article  CAS  PubMed  Google Scholar 

Reuss DE, Kratz A, Sahm F et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130:407–417

Article  CAS  PubMed  Google Scholar 

Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803

Article  PubMed  Google Scholar 

Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 22:515–523

Article  CAS  PubMed  Google Scholar 

Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693

Article  CAS  PubMed  Google Scholar 

Wijnenga MMJ, Dubbink HJ, French PJ et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959

Article  CAS  PubMed  Google Scholar 

Wijnenga MMJ, Maas SLN, van Dis V et al (2023) Glioblastoma lacking necrosis or vascular proliferations: different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation. Neurooncol Adv 5:vdad075

PubMed  PubMed Central  Google Scholar